PBTH presented today at the Jefferies meeting in N.Y.
The stock is up only 2.22% on volume about 1.5x its ADV
bigcharts.marketwatch.com
The company remains concentrated on four fronts:
HGH, Obesity, Interferon Beta, Factors VII and IX
They have filed for a PII on HGH and are awaiting approval. They expect that they will start this Summer and will be complete by the end of the Yr. or very early next Yr.
On the Obesity Drug, they still will be on pre-clinical development through the end of this Yr. and hope to commence a PI early next Yr. They are aware of the opportunity that this represents as it is currently a market where there is no approved product and has a huge potential.They feel that their product has a distinct advantage due to the probability of fewer if any side effects.
It is based on the general principle that the body produces an enzyme to to notify the brain its satiety. This enzyme’s action lasts for a very short time, but by prolonging its half life, and lasting much longer it will control hunger and the desire to eat. <g>
The work on Interferon Beta will also be at a pre-clinical stage through the end of this Yr.They expect to file for a PI early next Yr. It seems that they are seeking potential partners and is possible an announced on this front could come in the next 6 months. They would not be interested in taking this product to market without a partner due to the likely prohibitive costs of large long trials that would be too much for a small company to undertake.
The work on Factors VII and IX is also at pre-clinical stage and is expected to remain so for the rest of the Yr.
But they expect to file for a PII next Yr. and feel that a PI will not be required.
With PBTH main asset,the CTP, or Carboxyl Terminal Peptide technology, that can be attached to an array of existing therapeutic proteins,prolonging the half life,there is no shortage of ideas or opportunities and they expect to have some new targets in their pipeline next Yr. <g>
The great advantage of the CTP technology is that there are no known side effects.
MRK has submitted their CTP FSH product to the FDA, but the date for possible approval is not known.If approved, the stock could easily double from present levels.<g>
PPTH rang the opening bell on the NYSE last Thursday, but analyst coverage has been sparse.
Royalties and milestone payments that PBTH pays to Washington University on the CTP technology are small, and W.U.doesn't have any veto rights, PBTH doesn't have to wait for permission to move forward with any developments.
PBTH seems to have enough cash to be able to carry their operations through the end of 2012.Doctor Phillip Frost is the major holder of PBTH.
On June13 the stock will be added to some of the Tel Aviv stock indices, which will probably cause some purchasing in Israel.
AS mentioned, the ACTAY is $8
But it seems it could be higher if PBTH had a better analyst following.<g>
bigcharts.marketwatch.com
Bernard |
